Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition

Shuting Han1, Liyuan Zhu2, Yiran Zhu2

  • 1Department of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.

Theranostics
|August 10, 2021
PubMed

Insights

Inhibiting cancer cell glutaminolysis activates pro-survival autophagy via the ATF4 pathway. Targeting this autophagy enhances antitumor effects, offering a new strategy for cancer therapy.

Area of Science:

  • Cancer Metabolism
  • Molecular Oncology
  • Autophagy Research

Background:

  • Glutamine is crucial for cancer cell metabolism.
  • Inhibiting glutaminolysis is a potential anticancer strategy.
  • Glutaminolysis inhibition can paradoxically activate pro-survival autophagy, limiting its effectiveness.

Purpose of the Study:

  • Investigate the mechanism of autophagy activation following glutaminolysis inhibition.
  • Identify key molecular players in this adaptive response.
  • Explore therapeutic strategies to overcome autophagy-mediated resistance.

Main Methods:

  • High-throughput sequencing to identify differentially expressed genes in colorectal cancer (CRC) cells.
  • Gene set enrichment analysis to identify the activating transcription factor 4 (ATF4) pathway.
  • Quantitative real-time PCR (qRT-PCR), western blotting, and luciferase reporter assays to assess gene and protein expression and regulation.
  • mRNA half-life assays and RNA immunoprecipitation to investigate post-transcriptional regulation.
  • In vivo studies using a mouse model.

Main Results:

  • Glutaminolysis inhibition activated the ATF4 pathway in CRC cells.
  • ATF4 upregulated DNA damage inducible transcript 4 (DDIT4), suppressing mTOR and inducing pro-survival autophagy.
  • ATF4 mRNA expression was promoted by abrogating N6-methyladenosine (m6A) modification and YTHDF2-mediated RNA decay.
  • Inhibiting ATF4-induced autophagy enhanced the antitumor efficacy of glutaminolysis inhibition.

Conclusions:

  • Glutaminolysis inhibition upregulates ATF4 via an m6A-dependent manner, activating pro-survival autophagy through DDIT4 and mTOR inhibition.
  • Targeting ATF4-induced autophagy presents a novel strategy to synergize with glutaminolysis-targeting therapies for improved cancer treatment outcomes.

Related Concept Videos

Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.7K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K